Lisbeth N Morales-Rodriguez, Alex Rivera-Toquica, Clara Saldarriaga, Rolando Palacio, Luis M Avila-Barros, Silfredo Arrieta-Gonzalez, Alfonso Munoz-Velasquez, Eduardo J Echeverry-Navarrete, Julian R Lugo-Pena, Juan A Ceron, Luis E Silva-Diazgranados, Hugo E Osorio-Carmona, Luis E Echeverria, Juan E Gomez-Mesa
{"title":"哥伦比亚保留和轻度降低射血分数的心力衰竭的流行病学和短期结果:哥伦比亚心力衰竭登记处(RECOLFACA)的见解。","authors":"Lisbeth N Morales-Rodriguez, Alex Rivera-Toquica, Clara Saldarriaga, Rolando Palacio, Luis M Avila-Barros, Silfredo Arrieta-Gonzalez, Alfonso Munoz-Velasquez, Eduardo J Echeverry-Navarrete, Julian R Lugo-Pena, Juan A Ceron, Luis E Silva-Diazgranados, Hugo E Osorio-Carmona, Luis E Echeverria, Juan E Gomez-Mesa","doi":"10.14740/cr2015","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) has differences in therapy and development when compared with HF with reduced EF (HFrEF). We aimed to describe the clinical characteristics and all-cause mortality of patients with HFpEF/HFmrEF compared to those with HFrEF from the Colombian Heart Failure Registry (RECOLFACA).</p><p><strong>Methods: </strong>RECOLFACA included Colombian adult patients with ambulatory HF recruited from 2017 to 2019. All-cause mortality was our main outcome. We used the Kaplan-Meier method, life table, and Cox proportional hazard models to evaluate the role of the comorbidities on mortality, with a significant P-value of < 0.05. All statistical tests were two-tailed.</p><p><strong>Results: </strong>We included 2,514 patients, and 1,139 (45.3%) had a diagnosis of HFpEF or HFmrEF. HFpEF/HFmrEF diagnosis was not significantly related to either higher or lower risk of mortality compared to an HFrEF diagnosis; however, the individual risk factors for this outcome varied between the two groups. Health-related quality of life (HRQL) was a common risk factor for both groups.</p><p><strong>Conclusion: </strong>Although the EF classification was not a significant risk factor for mortality, patients with HFpEF/HFmrEF exhibited a unique profile of risk factors for mortality, the HRQL, highlighting the relevance of an adequate classification of the HF patients.</p>","PeriodicalId":9424,"journal":{"name":"Cardiology Research","volume":"16 3","pages":"267-277"},"PeriodicalIF":1.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074688/pdf/","citationCount":"0","resultStr":"{\"title\":\"Epidemiology and Short-Term Outcomes of Heart Failure With Preserved and Mildly Reduced Ejection Fraction in Colombia: Insights of the Colombian Heart Failure Registry (RECOLFACA).\",\"authors\":\"Lisbeth N Morales-Rodriguez, Alex Rivera-Toquica, Clara Saldarriaga, Rolando Palacio, Luis M Avila-Barros, Silfredo Arrieta-Gonzalez, Alfonso Munoz-Velasquez, Eduardo J Echeverry-Navarrete, Julian R Lugo-Pena, Juan A Ceron, Luis E Silva-Diazgranados, Hugo E Osorio-Carmona, Luis E Echeverria, Juan E Gomez-Mesa\",\"doi\":\"10.14740/cr2015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) has differences in therapy and development when compared with HF with reduced EF (HFrEF). We aimed to describe the clinical characteristics and all-cause mortality of patients with HFpEF/HFmrEF compared to those with HFrEF from the Colombian Heart Failure Registry (RECOLFACA).</p><p><strong>Methods: </strong>RECOLFACA included Colombian adult patients with ambulatory HF recruited from 2017 to 2019. All-cause mortality was our main outcome. We used the Kaplan-Meier method, life table, and Cox proportional hazard models to evaluate the role of the comorbidities on mortality, with a significant P-value of < 0.05. All statistical tests were two-tailed.</p><p><strong>Results: </strong>We included 2,514 patients, and 1,139 (45.3%) had a diagnosis of HFpEF or HFmrEF. HFpEF/HFmrEF diagnosis was not significantly related to either higher or lower risk of mortality compared to an HFrEF diagnosis; however, the individual risk factors for this outcome varied between the two groups. Health-related quality of life (HRQL) was a common risk factor for both groups.</p><p><strong>Conclusion: </strong>Although the EF classification was not a significant risk factor for mortality, patients with HFpEF/HFmrEF exhibited a unique profile of risk factors for mortality, the HRQL, highlighting the relevance of an adequate classification of the HF patients.</p>\",\"PeriodicalId\":9424,\"journal\":{\"name\":\"Cardiology Research\",\"volume\":\"16 3\",\"pages\":\"267-277\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12074688/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/cr2015\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/cr2015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Epidemiology and Short-Term Outcomes of Heart Failure With Preserved and Mildly Reduced Ejection Fraction in Colombia: Insights of the Colombian Heart Failure Registry (RECOLFACA).
Background: Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) has differences in therapy and development when compared with HF with reduced EF (HFrEF). We aimed to describe the clinical characteristics and all-cause mortality of patients with HFpEF/HFmrEF compared to those with HFrEF from the Colombian Heart Failure Registry (RECOLFACA).
Methods: RECOLFACA included Colombian adult patients with ambulatory HF recruited from 2017 to 2019. All-cause mortality was our main outcome. We used the Kaplan-Meier method, life table, and Cox proportional hazard models to evaluate the role of the comorbidities on mortality, with a significant P-value of < 0.05. All statistical tests were two-tailed.
Results: We included 2,514 patients, and 1,139 (45.3%) had a diagnosis of HFpEF or HFmrEF. HFpEF/HFmrEF diagnosis was not significantly related to either higher or lower risk of mortality compared to an HFrEF diagnosis; however, the individual risk factors for this outcome varied between the two groups. Health-related quality of life (HRQL) was a common risk factor for both groups.
Conclusion: Although the EF classification was not a significant risk factor for mortality, patients with HFpEF/HFmrEF exhibited a unique profile of risk factors for mortality, the HRQL, highlighting the relevance of an adequate classification of the HF patients.
期刊介绍:
Cardiology Research is an open access, peer-reviewed, international journal. All submissions relating to basic research and clinical practice of cardiology and cardiovascular medicine are in this journal''s scope. This journal focuses on publishing original research and observations in all cardiovascular medicine aspects. Manuscript types include original article, review, case report, short communication, book review, letter to the editor.